Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $42.20.

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded Attovia Therapeutics to a “sell” rating in a research note on Saturday, September 19th. Morgan Stanley assumed coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “overweight” rating and a $39.00 price target on the stock. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock. Leerink Partners initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $52.00 target price for the company. Finally, Citigroup started coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued a “buy” rating and a $30.00 target price for the company.

View Our Latest Stock Analysis on ATTO

Insider Activity at Attovia Therapeutics

In related news, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the transaction, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. This trade represents a 10.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average price of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the transaction, the insider owned 4,181,367 shares in the company, valued at $71,083,239. This represents a 10.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 2,740,587 shares of company stock worth $47,269,979 in the last ninety days.

Attovia Therapeutics Price Performance

ATTO opened at $15.80 on Thursday. The company has a market capitalization of $721.27 million and a PE ratio of -3.24. Attovia Therapeutics has a twelve month low of $12.94 and a twelve month high of $28.00. The business’s 50-day moving average price is $18.91.

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The company had revenue of $0.45 million for the quarter. Sell-side analysts anticipate that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.

See Also

Analyst Recommendations for Attovia Therapeutics (NASDAQ:ATTO)

Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.